Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review

Hum Vaccin Immunother. 2024 Dec 31;20(1):2313860. doi: 10.1080/21645515.2024.2313860. Epub 2024 Feb 15.

Abstract

The primary objective of this paper is to serve as a valuable resource for policymakers who are confronted with the evolving landscape of the coronavirus disease 2019 (COVID-19), considering both free and cost-based vaccination approaches. The potential consequences of shifting from free to cost-based vaccination are explored, encompassing its impact on global vaccine equity and prioritization, economic well-being, healthcare systems and delivery, public health policies, and vaccine distribution strategies. Examining past studies on willingness to pay for the initial COVID-19 vaccine dose and booster shots provides insights into how individuals value COVID-19 vaccinations and underscores the significance of addressing issues related to affordability. If COVID-19 vaccinations incur expenses, using effective communication strategies that emphasize the importance of vaccination and personal health benefits can increase willingness to pay. Making COVID-19 vaccines accessible through public health programs or health insurance can help alleviate financial barriers and increase vaccination rates.

Keywords: COVID-19; Cost-based vaccination; willingness to pay.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Immunization, Secondary
  • Pandemics
  • Vaccination

Substances

  • COVID-19 Vaccines

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article..